CA125CA199联合检测在卵巢癌中临床应用分析.docVIP

CA125CA199联合检测在卵巢癌中临床应用分析 　　【摘要】 目的 探讨CA125单独和联合CA199检测在卵巢癌临床应用进行分析。方法 回顾我院2008年1月至2009年10月住院的卵巢癌患者296例,观察卵巢癌组、对照组血清CA199、CA125水平及阳性检测率。对CA125单独及联合CA199检测观察对卵巢癌阳性检测率进行观察比较。结果 卵巢癌组CA199阳性134例,阳性率45.27%;CA125阳性228例,阳性率77.02%;CA125单独及联合CA199检测敏感性、特异性、准确性比较P0.05差异有统计学意义。结论 CA125,CA199联合检测对卵巢癌患者进行血清肿瘤标志物检测时应用多种肿瘤标志物同时进行检测,提高阳性率,减少误诊和漏诊,提高早期诊断和及早进行疾病治疗,延长患者的生命。 　　【关键词】卵巢癌;CA125、CA199;联合检测;临床应用 　　 　　CA125,CA199 in ovarian cancer combined detection of clinical application of analysis of 　　XU Xiu hua. 　　Gynecology and obstetrics department Henan Province Shangqiu first people hospital,Shangqiu 476100,China 　　【Abstract】 Objective To explore the individual and joint CA199 detection of CA125 in ovarian cancer clinical analysis.Methods Looking back at my hospital in January 2008 to octobe 2,009 year hospitalized 　　patients with 296 cases of ovarian cancer was observed ovarian cancer group and control group serum CA199,CA125 level and the positive detection rate.Right CA125 alone or in combination CA199 observation of ovarian cancer detection rate of positive test observed and compared.Results The ovarian cancer group CA199 positive for 134 cases,the positive rate of 45.27%; CA125 positive for 228 cases,the positive rate of 77.02%; CA125 alone or in combination CA199 detection sensitivity,specificity and accuracy comparison P0.05 significant differences.Conclusion CA125,CA199 combined detection of ovarian cancer patients with serum tumor markers in detection using a variety of tumor markers for detection at the same time,improve the positive rate,reduce misdiagnosis and missed diagnosis,to improve the early diagnosis and early treatment of disease and prolong life in patients with. 　　【Key words】Ovarian cancer; CA125,CA199; Joint detection; Clinical application 　　 　　卵巢上皮癌是女性三大恶性肿瘤之一,是妇科恶性肿瘤的首要死亡原因[1]。近年来卵巢癌的发病率有逐年升高的趋势,严重影响女性的生存时间和生存质量。卵巢癌由于位于盆腔且在肿瘤早期无典型的临床表现,有明确的临床表现并确诊时60%~70%已是晚期[2],为了能够提高对本病的早期诊断和早期治疗,延长患者的生存时间和生存质量。我们采用多种血清肿瘤标志物联合检测,用于提高对卵巢癌检测的阳性率和准确率,达到了良好的临床效果,现汇报如下。 　　1 资